Equities

bioAffinity Technologies Inc

BIAF:NAQ

bioAffinity Technologies Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)2.06
  • Today's Change0.05 / 2.49%
  • Shares traded155.17k
  • 1 Year change+33.77%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects bioAffinity Technologies Inc share price to rise to 6.00 in the next year from the last price of 2.06.
High191.3%6.00
Med191.3%6.00
Low191.3%6.00

Earnings history & estimates in USD

On Aug 14, 2024, bioAffinity Technologies Inc reported 2nd quarter 2024 losses of -0.19 per share.
The next earnings announcement is expected on Dec 06, 2024.
bioAffinity Technologies Inc reported annual 2023 losses of -0.91 per share on Apr 01, 2024.
Average growth rate+49.72%
More ▼

Revenue history & estimates in USD

bioAffinity Technologies Inc had 2nd quarter 2024 revenues of 2.40m. This missed the 2.45m estimate of the one analyst following the company. The same period last year the company did not report revenues.
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.